NASDAQ:BOLT • US0977022039
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BOLT BIOTHERAPEUTICS INC (BOLT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-15 | Lake Street | Maintains | Buy -> Buy |
| 2025-05-20 | Lake Street | Initiate | Buy |
| 2025-05-13 | Stifel | Maintains | Hold -> Hold |
| 2025-03-25 | Stifel | Maintains | Hold -> Hold |
| 2025-03-25 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Neutral |
| 2024-05-15 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-05-15 | Jones Trading | Downgrade | Buy -> Hold |
| 2024-05-15 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-05-15 | Stifel | Downgrade | Buy -> Hold |
| 2024-05-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-03-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-06-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-26 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-05-12 | SVB Leerink | Upgrade | Market Perform -> Outperform |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-30 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-24 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-10-04 | HC Wainwright & Co. | Initiate | Buy |
| 2022-08-11 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-05-17 | Morgan Stanley | Maintains | Equal-Weight |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 5.73M 354.76% | 7.876M 37.45% | 7.69M -2.36% | 5.234M -31.94% | 2.38M -54.53% | 153K -93.57% | 17M 11,011.11% | 25.5M 50.00% | 25.5M | -100.00% | ||
| EBITDA YoY % growth | -88.65M 3.22% | -74.342M 16.14% | -66.455M 10.61% | -124.671M -87.60% | -138.759M -11.30% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -90.32M 2.66% | -76.196M 15.64% | -68.236M 10.45% | -38.509M 43.57% | -28.941M 24.85% | -28.56M 1.32% | -57.717M -102.09% | -57.421M 0.51% | -54.938M 4.33% | 225.93M 511.25% | N/A | |
| Operating Margin | -1,576.27% | -967.45% | -887.33% | -735.74% | -1,216.01% | -18,666.67% | -339.51% | -225.18% | -215.44% | N/A | N/A | |
| EPS YoY % growth | -47.20 24.84% | -36.60 22.46% | -30.40 16.94% | -21.65 28.78% | -19.87 8.22% | -20.83 -4.83% | -22.24 -6.78% | -20.65 7.15% | -19.77 4.25% | 2.58 113.05% | N/A |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -6.23 18.04% | -4.29 26.05% | -3.18 28.76% | -2.84 23.64% | -2.61 58.16% |
| Revenue Q2Q % growth | 680.003K | 969K -20.70% | 918K -49.11% | 867K -60.03% | 867K 27.50% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.863M 43.43% | -8.085M 33.39% | -7.935M 13.85% | -7.792M -1.15% | -7.653M 13.65% |
All data in USD
11 analysts have analysed BOLT and the average price target is 27.29 USD. This implies a price increase of 597.83% is expected in the next year compared to the current price of 3.91.
BOLT BIOTHERAPEUTICS INC (BOLT) will report earnings on 2026-03-23, after the market close.
The consensus EPS estimate for the next earnings of BOLT BIOTHERAPEUTICS INC (BOLT) is -6.23 USD and the consensus revenue estimate is 680.00K USD.
The consensus rating for BOLT BIOTHERAPEUTICS INC (BOLT) is 76.3636 / 100 . This indicates that analysts generally have a positive outlook on the stock.